Trials / Not Yet Recruiting
Not Yet RecruitingNCT06925659
A Study of QLM2011 in Subjects With Advanced Solid Tumors
A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity of QLM2011 in Patients With Advanced Solid Tumors
- Status
- Not Yet Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 172 (estimated)
- Sponsor
- Qilu Pharmaceutical (Hainan) Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
This trial is an open-label, single-center, dose-escalation and cohort-expansion Phase I clinical study in patients with advanced solid tumors. The purposeaim of this study is designed to evaluate the safety, tolerability, pharmacokinetics and preliminary antitumor activity of QLM2011 in patients with advanced solid tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | QLM2011 | QLM2011l by intravenous infusion. |
| DRUG | Taxotere® | Taxotere® by intravenous infusion |
Timeline
- Start date
- 2025-05-01
- Primary completion
- 2026-06-01
- Completion
- 2027-02-01
- First posted
- 2025-04-13
- Last updated
- 2025-04-17
Source: ClinicalTrials.gov record NCT06925659. Inclusion in this directory is not an endorsement.